Janssen’s psoriasis drug shows promise for childhood diabetes
Type 1 diabetes accounts for approximately 10% of diabetes cases in the UK
Read More
Tag: ustekinumab
US expands scope of Janssen’s Stelara
The new approval cover paediatric patients with plaque psoriasis
Read More
Final NICE green light for Janssen’s Stelara in UC
The drug will be funded on the NHS to treat ulcerative colitis under certain conditions
Read More
NICE u-turn backs Stelara for UC
Stelara is the first biologic therapy for UC that targets interleukin (IL)-12 and IL-23 cytokines
Read More
Janssen files Stelara in Europe for ulcerative colitis
Janssen has submitted an application to the European Medicines Agency (EMA) seeking to expand the approval of Stelara to include the treatment of adults with moderately to severely active ulcerative colitis (UC).
Read More
Stelara induces remission in ulcerative colitis patients
Janssen has presented new data showing that a single dose of its biologic Stelara induced clinical remission and response in patients with moderate to severe ulcerative colitis.
Read More
Novartis’ Cosentyx beats J&J’s Stelara in psoriasis trial
Novartis has released trial data showing that Cosentyx was “significantly more effective” than Johnson & Johnson’s rival biologic Stelara in achieving clear skin in patients with psoriasis.
Read More
US expands scope of J&J’s biologic Stelara in psoriasis
US regulators have approved an expansion of Johnson & Johnson’s Stelara to include younger patients with plaque psoriasis.
Read More
EU approves LEO Pharma’s psoriasis biologic
A new treatment option has been approved in the European Union for patients with psoriasis, paving the way for access to a novel approach for those with moderate-to-severe forms of the disease who are candidates for systemic therapy.
Read More
NICE backs Humira, Enbrel and Stelara for plaque psoriasis in children
AbbVie’s Humira, Pfizer’s Enbrel, and Janssen’s Stelara are being recommended as options for treating plaque psoriasis in children and young people on the NHS.
Read More
SMC bars access to Actelion’s Uptravi on NHS Scotland
Actelion says it is disappointed with a decision by Scottish cost regulators to refuse NHS funding for pulmonary arterial hypertension drug Uptravi.
Read More
NICE backs new option for Crohn’s disease
The National Institute for Health and Care Excellence is backing the use of Janssen’s biologic Stelara to treat adult patients with moderately to severely active Crohn’s disease.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
